Share
𝕏 Facebook LinkedIn

Effect of lansoprazole on the epigastric symptoms of functional dyspepsia (ELF study): A multicentre, prospective, randomized, double-blind, placebo-controlled clinical trial.

PAPER pubmed United European gastroenterology journal 2013 Randomized trial Effect: benefit Evidence: Moderate

Abstract

BACKGROUND: Since the publication of the Rome III criteria for functional dyspepsia (FD), the evidence about the efficacy of half-dose of proton pump inhibitors for dyspepsia symptoms have been limited. OBJECTIVE: To examine the efficacy of lansoprazole for functional dyspepsia (FD) diagnosed with the Rome III criteria by the multicentre, double-blind, randomized, placebo-controlled study in Japan. METHODS: A total of 54 FD participants were randomized to lansoprazole 15 mg once daily or placebo for a 4-week double-blind treatment period. The primary efficacy endpoint was an overall dyspeptic symptom relief rate evaluated by 5-point Likert scale scores. The alteration of dyspeptic symptom scores during the study period was also assessed. RESULTS: At week 4, the overall dyspeptic symptom relief rates were higher in the lansoprazole group (30.4%) than in the placebo group (6.7%) (p = 0.045). The scores for epigastric pain (p = 0.045) and epigastric burning (p = 0.03) were significantly improved in the lansoprazole group compared to the placebo group, whereas the improvement of the scores for postprandial fullness (p = 0.81) and early satiation (p = 0.33) was not different between lansoprazole and placebo groups. CONCLUSIONS: Lansoprazole 15 mg ameliorates dyspeptic symptoms, particularly the epigastric pain syndrome-related symptoms of FD.

AI evidence extraction

At a glance
Study type
Randomized trial
Effect direction
benefit
Population
Participants with functional dyspepsia (FD) diagnosed with the Rome III criteria in Japan
Sample size
54
Exposure
· 4-week double-blind treatment period
Evidence strength
Moderate
Confidence: 74% · Peer-reviewed: yes

Main findings

At week 4, overall dyspeptic symptom relief was higher with lansoprazole 15 mg once daily (30.4%) than placebo (6.7%) (p=0.045). Epigastric pain (p=0.045) and epigastric burning (p=0.03) improved significantly versus placebo, while postprandial fullness (p=0.81) and early satiation (p=0.33) did not differ between groups.

Outcomes measured

  • Overall dyspeptic symptom relief rate (5-point Likert scale)
  • Epigastric pain score
  • Epigastric burning score
  • Postprandial fullness score
  • Early satiation score

Limitations

  • Small sample size (n=54)
  • Short treatment duration (4 weeks)
View raw extracted JSON
{
    "study_type": "randomized_trial",
    "exposure": {
        "band": null,
        "source": null,
        "frequency_mhz": null,
        "sar_wkg": null,
        "duration": "4-week double-blind treatment period"
    },
    "population": "Participants with functional dyspepsia (FD) diagnosed with the Rome III criteria in Japan",
    "sample_size": 54,
    "outcomes": [
        "Overall dyspeptic symptom relief rate (5-point Likert scale)",
        "Epigastric pain score",
        "Epigastric burning score",
        "Postprandial fullness score",
        "Early satiation score"
    ],
    "main_findings": "At week 4, overall dyspeptic symptom relief was higher with lansoprazole 15 mg once daily (30.4%) than placebo (6.7%) (p=0.045). Epigastric pain (p=0.045) and epigastric burning (p=0.03) improved significantly versus placebo, while postprandial fullness (p=0.81) and early satiation (p=0.33) did not differ between groups.",
    "effect_direction": "benefit",
    "limitations": [
        "Small sample size (n=54)",
        "Short treatment duration (4 weeks)"
    ],
    "evidence_strength": "moderate",
    "confidence": 0.7399999999999999911182158029987476766109466552734375,
    "peer_reviewed_likely": "yes",
    "keywords": [
        "functional dyspepsia",
        "Rome III criteria",
        "lansoprazole",
        "proton pump inhibitor",
        "randomized",
        "double-blind",
        "placebo-controlled",
        "epigastric pain syndrome"
    ],
    "suggested_hubs": []
}

AI can be wrong. Always verify against the paper.

AI-extracted fields are generated from the abstract/metadata and may be incomplete or incorrect. This content is for informational purposes only and is not medical advice.

Comments

Log in to comment.

No comments yet.